Biogazelle focuses on developing RNA-targeting drugs in the field of oncology. Therapeutic programs build on the synergy between the cancer type specific expression of long non-coding RNAs (lncRNAs), and the self-delivering capacity and target-specificity of nucleic acid-based drugs, to develop safe and effective therapies.


Biogazelle has proprietary knowledge to prioritize candidate therapeutic RNA targets in specific cancer types, building on years of expertise in exploring the transcriptome as 'RNA solutions' service provider. Therapeutic inhibition of candidate lncRNA targets is being evaluated in large-scale in vitro screenings and in preclinical animal models. Nucleic acid-based drug technologies are in-licensed through partnerships.


Biogazelle’s therapeutic programs are currently focused on colon, liver and lung cancer.


We welcome opportunities for partnering and collaboration. Contact us at to request more information.